Mark Rosen, PA
Medical · Berkley, MINPI 1588101091
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 45 manufacturers reported payments, led by Viiv Healthcare Company at 50.0% of the total. Reporting peaked in 2021 at $15,635 and has fallen 83.1% since, to $2,638 in 2025. Among medical clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,041 payments — averaging $30.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$16K
- Gilead$5K
- Merck$3K
- Johnson & Johnson$1K
- AbbVie$923
- Novo Nordisk$646
- plus $5K from 39 others
Across 8 payments — averaging $246.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$2K
What the payments were for
- Speaking & faculty fees$10,97235%
- Travel & lodging$2,5908%
- Food & beverage$18,00357%
- Education$1260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$31,690 in reported general payments places this provider in the 95th percentile of 755 medical providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 201 | $795,966 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 36 | $167,515 |
| DescovyEmtricitabine/Tenofov Alafenam | 68 | $142,235 |
| DovatoDolutegravir Sodium/Lamivudine | 43 | $131,531 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 28 | $96,358 |
| TivicayDolutegravir Sodium | 33 | $86,435 |
| CabenuvaCabotegravir/Rilpivirine | 13 | $86,298 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 19 | $73,920 |
| MounjaroTirzepatide | 38 | $44,314 |
| JulucaDolutegravir/Rilpivirine | 13 | $40,381 |
| Nurtec OdtRimegepant Sulfate | 19 | $35,439 |
| JardianceEmpagliflozin | 42 | $34,067 |
| DelstrigoDoravirine/Lamivu/Tenofov Diso | 12 | $31,641 |
| EliquisApixaban | 18 | $22,089 |
| TrulicityDulaglutide | 23 | $21,523 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $4,549 | $938,201269 claims |
| Viiv Healthcare CompanyDovato, Tivicay, Cabenuva, Triumeq, Juluca | $15,831 | $418,565121 claims |
| Janssen Products, LPSymtuza | $234 | $167,51536 claims |
| Lilly USA, LLCMounjaro, Trulicity | $396 | $65,83761 claims |
| PfizerNurtec Odt, Eliquis, Premarin | $394 | $61,86151 claims |
| Boehringer IngelheimJardiance | $148 | $34,06742 claims |
| MerckDelstrigo | $3,222 | $31,64112 claims |
| AstraZenecaFarxiga | $468 | $19,62922 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $123 | $15,92611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 755 medical providers in Michigan.
Other medical in Berkley
- Caleb YoungbloodBerkley$215K
- Mayuri BharathanBerkley$8K
- Steven StoneKalamazoo$200K
- Meredith KentGrand Rapids$192K
- Amber ShullNorton Shores$154K
- Jason EvansWaterford$104K
- James ToreySaint Clair Shores$56K
- David WilkinsMuskegon$41K
- Robert DemeesterRoyal Oak$27K
- John BrabantDetroit$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.